
XOMA Completes \$10 Million Debt Financing

Date: 12/30/11

Cahill represented XOMA Corporation, a leader in the discovery and development of antibody therapeutics, and its subsidiaries in connection with a \$10.0 million 42-month secured term loan agreement with GE Capital Corporation. The funds will be used for advancement of gevokizumab (XOMA 052), XOMA's lead clinical product candidate, and for general corporate purposes.

Attorneys

- Geoffrey E. Liebmann
- Anastasia Efimova
- Ross Sturman